ARA 290

• Neuropathic pain (e.g., diabetic neuropathy, sarcoidosis-related small fiber neuropathy)
• Inflammatory diseases (e.g., inflammatory bowel disease, multiple sclerosis)
• Tissue and organ protection (e.g., ischemia-reperfusion injury, kidney and cardiovascular protection)
• Wound healing
• Neuroprotection and nerve regeneration

Binding to IRR: Targets the innate repair receptor (IRR), not the classical EPO receptor, to activate regenerative responses.
Activation of Tissue Protection Pathways: Stimulates anti-apoptotic and pro-repair mechanisms, enhancing cell survival and tissue restoration.
Anti-Inflammatory Effects: Reduces cytokines (TNF-α, IL-1β, IL-6) and inhibits inflammatory cell recruitment.
Neuropathic Pain Relief: Modulates pain and inflammation pathways, improving nerve function

1. Small Fiber Neuropathy (SFN)

• Study focus: Sarcoidosis-associated SFN
• Key findings: Improved nerve fiber density and reduced pain
• Reference: Heij et al., Pain Medicine, 2012

2. Neuropathic Pain Relief

• Study focus: Diabetic neuropathy
• Key findings: Lowered pain scores; minimal side effects
• Reference: Brines et al., Molecular Medicine, 2015

3. Anti-Inflammatory Properties

• Study focus: Animal models of inflammatory disease
• Key findings: Decreased TNF-α, IL-1β, IL-6; protected tissues
• Reference: Brines et al., Science Translational Medicine, 2008

4. Kidney Protection

• Study focus: Renal ischemia-reperfusion injury in mice
• Key findings: Reduced oxidative stress and tissue damage
• Reference: van Velzen et al., Kidney International, 2014

5. Clinical Trials Summary

• Study focus: Multiple Phase II trials for neuropathic pain
• Key findings: Pain relief, nerve repair, minimal adverse events📚 How to Access Full Studies

To explore these studies in detail, you can visit:

1. PubMed – Search using terms like "ARA 290 peptide neuropathy".
2. Google Scholar – For academic research articles.
3. ClinicalTrials.gov – For clinical trial
statuses.